276 related articles for article (PubMed ID: 12377770)
61. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
62. Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in (S)-3,5-dihydroxyphenylglycene-induced long term depression.
Huang CC; You JL; Wu MY; Hsu KS
J Biol Chem; 2004 Mar; 279(13):12286-92. PubMed ID: 14709549
[TBL] [Abstract][Full Text] [Related]
63. Role of the p38 MAPK pathway in cisplatin-based therapy.
Hernández Losa J; Parada Cobo C; Guinea Viniegra J; Sánchez-Arevalo Lobo VJ; Ramón y Cajal S; Sánchez-Prieto R
Oncogene; 2003 Jun; 22(26):3998-4006. PubMed ID: 12821934
[TBL] [Abstract][Full Text] [Related]
64. Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK.
Nishihara H; Hwang M; Kizaka-Kondoh S; Eckmann L; Insel PA
J Biol Chem; 2004 Jun; 279(25):26176-83. PubMed ID: 15078890
[TBL] [Abstract][Full Text] [Related]
65. p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2.
Li SP; Junttila MR; Han J; Kähäri VM; Westermarck J
Cancer Res; 2003 Jul; 63(13):3473-7. PubMed ID: 12839928
[TBL] [Abstract][Full Text] [Related]
66. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
67. p38 Mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation.
Dean JL; Sarsfield SJ; Tsounakou E; Saklatvala J
J Biol Chem; 2003 Oct; 278(41):39470-6. PubMed ID: 12882963
[TBL] [Abstract][Full Text] [Related]
68. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
[TBL] [Abstract][Full Text] [Related]
69. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration.
Jo M; Thomas KS; Somlyo AV; Somlyo AP; Gonias SL
J Biol Chem; 2002 Apr; 277(14):12479-85. PubMed ID: 11805108
[TBL] [Abstract][Full Text] [Related]
70. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock.
Uhlik MT; Abell AN; Johnson NL; Sun W; Cuevas BD; Lobel-Rice KE; Horne EA; Dell'Acqua ML; Johnson GL
Nat Cell Biol; 2003 Dec; 5(12):1104-10. PubMed ID: 14634666
[TBL] [Abstract][Full Text] [Related]
71. Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat hepatocytes.
Kietzmann T; Samoylenko A; Immenschuh S
J Biol Chem; 2003 May; 278(20):17927-36. PubMed ID: 12637567
[TBL] [Abstract][Full Text] [Related]
72. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
[TBL] [Abstract][Full Text] [Related]
73. MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription.
Benasciutti E; Pagès G; Kenzior O; Folk W; Blasi F; Crippa MP
Blood; 2004 Jul; 104(1):256-62. PubMed ID: 15031204
[TBL] [Abstract][Full Text] [Related]
74. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice.
Lu HT; Yang DD; Wysk M; Gatti E; Mellman I; Davis RJ; Flavell RA
EMBO J; 1999 Apr; 18(7):1845-57. PubMed ID: 10202148
[TBL] [Abstract][Full Text] [Related]
75. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation.
Abraham E; Gyetko MR; Kuhn K; Arcaroli J; Strassheim D; Park JS; Shetty S; Idell S
J Immunol; 2003 Jun; 170(11):5644-51. PubMed ID: 12759445
[TBL] [Abstract][Full Text] [Related]
76. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Guo Y; Pakneshan P; Gladu J; Slack A; Szyf M; Rabbani SA
J Biol Chem; 2002 Nov; 277(44):41571-9. PubMed ID: 12198113
[TBL] [Abstract][Full Text] [Related]
77. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid.
Alsayed Y; Uddin S; Mahmud N; Lekmine F; Kalvakolanu DV; Minucci S; Bokoch G; Platanias LC
J Biol Chem; 2001 Feb; 276(6):4012-9. PubMed ID: 11060298
[TBL] [Abstract][Full Text] [Related]
78. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes.
Inoue T; Hammaker D; Boyle DL; Firestein GS
J Immunol; 2005 Apr; 174(7):4301-6. PubMed ID: 15778394
[TBL] [Abstract][Full Text] [Related]
79. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
80. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
Nielsen TO; Andrews HN; Cheang M; Kucab JE; Hsu FD; Ragaz J; Gilks CB; Makretsov N; Bajdik CD; Brookes C; Neckers LM; Evdokimova V; Huntsman DG; Dunn SE
Cancer Res; 2004 Jan; 64(1):286-91. PubMed ID: 14729636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
